Rhythm Pharmaceuticals Announced Plans To Add A Cohort Of Patients With Hypothalamic Obesity In Japan To Its Ongoing Global Phase 3 Clinical Trial Of Setmelanotide, With Dosing Expected To Begin In The Third Quarter Of 2024
Benzinga Newsdesk - Feb 22, 2024, 7:09AM